产品说明书
AZD-5069
 |
同义名 : | - |
| CAS号 : | 878385-84-3 | |
| 货号 : | A912767 | |
| 分子式 : | C18H22F2N4O5S2 | |
| 纯度 : | 99%+ | |
| 分子量 : | 476.518 | |
| MDL号 : | MFCD19443645 | |
| 存储条件： |
粉末 Keep in dark place,Inert atmosphere,Store in freezer, under -20°C 液体 -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 95 mg/mL(199.36 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | AZD-5069 is a CXCR2 antagonist by blocking [125I]-IL-8 binding to human CXCR2 receptors and by inhibiting GROα-induced calcium flux in human neutrophils that are loaded with the fluo-3 dye[1]. | ||
| 临床研究 | |||||
|---|---|---|---|---|---|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT02499328 | Advanced Solid Tumors & Metast... 展开 >>atic Squamous Cell Carcinoma of the Head and Neck 收起 << | Phase 1 Phase 2 | Recruiting | October 31, 2019 | - |
| NCT01962935 | Chronic Obstructive Pulmonary ... 展开 >>Disease (COPD). 收起 << | Phase 1 | Completed | - | United Kingdom ... 展开 >> Research Site London, United Kingdom 收起 << |
| NCT01989520 | Uncontrolled and Persistent As... 展开 >>thma 收起 << | Phase 1 | Completed | - | United Kingdom ... 展开 >> Research Site London, United Kingdom 收起 << |
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
2.10mL 0.42mL 0.21mL |
10.49mL 2.10mL 1.05mL |
20.99mL 4.20mL 2.10mL |
| 参考文献 |
|---|